Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Avidity Biosciences ( (RNA) ) is now available.
On June 9, 2025, Avidity Biosciences announced the initiation of a global Phase 3 study for del-brax, following FDA feedback on an accelerated approval pathway for treating FSHD. The company also revealed positive topline data from its Phase 1/2 FORTITUDE trial, showing improvements in functional mobility, muscle strength, and quality of life, alongside favorable safety results. These developments potentially enhance Avidity’s market positioning and offer hope for FSHD patients.
The most recent analyst rating on (RNA) stock is a Buy with a $56.00 price target. To see the full list of analyst forecasts on Avidity Biosciences stock, see the RNA Stock Forecast page.
Spark’s Take on RNA Stock
According to Spark, TipRanks’ AI Analyst, RNA is a Neutral.
Avidity Biosciences’ stock score is influenced mainly by financial performance struggles and valuation issues, as reflected in negative profitability indicators. However, technical indicators show positive momentum, counterbalancing some financial concerns. The recent positive trial results could improve future prospects, but immediate financial health remains a challenge.
To see Spark’s full report on RNA stock, click here.
More about Avidity Biosciences
Avidity Biosciences operates in the biotechnology industry, focusing on the development of RNA therapeutics. The company’s primary product is delpacibart braxlosiran (del-brax), which targets facioscapulohumeral muscular dystrophy (FSHD).
Average Trading Volume: 1,494,267
Technical Sentiment Signal: Strong Buy
Current Market Cap: $4.37B
Learn more about RNA stock on TipRanks’ Stock Analysis page.